Pharmacotherapy of systolic heart failure: emphasis on mortality outcomes.
Mortality outcomes in clinical trials have become the foundation for the evidence-based management of patients with systolic heart failure. This review was intended to give the clinician a better understanding of newer pharmacological strategies in this patient population.
Barbour
M M
MM
Department of Pharmacy Practice, University of Rhode Island, 41 Lower College Road, Kingston, RI 02881, USA. MbarbourRI@aol.com
Zuwallack
A
A
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D004077:Digoxin / Q000627:therapeutic use; D006333:Heart Failure / Q000188:drug therapy* / Q000401:mortality*; D006801:Humans; D000451:Mineralocorticoid Receptor Antagonists / Q000009:adverse effects / Q000627:therapeutic use; D013148:Spironolactone / Q000009:adverse effects / Q000627:therapeutic use; D016019:Survival Analysis
D000319:Adrenergic beta-Antagonists; D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000451:Mineralocorticoid Receptor Antagonists; D013148:Spironolactone; D004077:Digoxin